Balancing the risks and benefits of biologic therapy in inflammatory bowel diseases
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Balancing the risks and benefits of biologic therapy in inflammatory bowel diseases
Authors
Keywords
-
Journal
Expert Opinion On Drug Safety
Volume 14, Issue 12, Pages 1915-1934
Publisher
Informa Healthcare
Online
2015-11-11
DOI
10.1517/14740338.2015.1108961
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Vedolizumab: An integrin-receptor antagonist for treatment of Crohn's disease and ulcerative colitis
- (2015) L. Hahn et al. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
- High Prevalence of Inflammatory Bowel Disease in United States Residents of Indian Ancestry
- (2015) Reenu Malhotra et al. Clinical Gastroenterology and Hepatology
- Treat to Target: A Proposed New Paradigm for the Management of Crohn's Disease
- (2015) Guillaume Bouguen et al. Clinical Gastroenterology and Hepatology
- Comparative Effectiveness of Immunosuppressants and Biologics for Inducing and Maintaining Remission in Crohn's Disease: A Network Meta-analysis
- (2015) Glen S. Hazlewood et al. GASTROENTEROLOGY
- Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis
- (2015) Johannan F. Brandse et al. GASTROENTEROLOGY
- Converging Goals of Treatment of Inflammatory Bowel Disease From Clinical Trials and Practice
- (2015) Barrett G. Levesque et al. GASTROENTEROLOGY
- 865 PIANO: A 1000 Patient Prospective Registry of Pregnancy Outcomes in Women With IBD Exposed to Immunomodulators and Biologic Therapy
- (2015) Uma Mahadevan et al. GASTROENTEROLOGY
- Long-term safety and efficacy of certolizumab pegol in the treatment of Crohn's disease: 7-year results from the PRECiSE 3 study
- (2014) W. J. Sandborn et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Review article: anti-adhesion therapies for inflammatory bowel disease
- (2014) T. Lobatón et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Drug Therapies and the Risk of Malignancy in Crohn's Disease: Results From the TREAT™ Registry
- (2014) Gary R Lichtenstein et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Biological Agents for Moderately to Severely Active Ulcerative Colitis
- (2014) Silvio Danese et al. ANNALS OF INTERNAL MEDICINE
- Pegylation of Biological Molecules and Potential Benefits: Pharmacological Properties of Certolizumab Pegol
- (2014) Gianfranco Pasut BIODRUGS
- Postoperative Therapy With Infliximab Prevents Long-term Crohn’s Disease Recurrence
- (2014) Miguel Regueiro et al. Clinical Gastroenterology and Hepatology
- Efficacy and safety of adalimumab for the Crohn’s disease: a systematic review and meta-analysis of published randomized placebo-controlled trials
- (2014) Yun-Na Song et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Length of hospital stay and associated hospital costs with infliximab versus cyclosporine in severe ulcerative colitis
- (2014) Mark Löwenberg et al. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
- Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed
- (2014) Bruce E. Sands et al. GASTROENTEROLOGY
- Update on Anti-Tumor Necrosis Factor Agents in Crohn Disease
- (2014) Siddharth Singh et al. GASTROENTEROLOGY CLINICS OF NORTH AMERICA
- Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial
- (2014) Freddy Cornillie et al. GUT
- Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE
- (2013) R. Panaccione et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Adalimumab Is More Effective Than Azathioprine and Mesalamine at Preventing Postoperative Recurrence of Crohn's Disease: A Randomized Controlled Trial
- (2013) Edoardo Savarino et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Demyelination and other neurological adverse events after anti-TNF therapy
- (2013) Evripidis Kaltsonoudis et al. AUTOIMMUNITY REVIEWS
- Dual Therapy With Infliximab and Immunomodulator Reduces One-Year Rates of Hospitalization and Surgery Among Veterans With Inflammatory Bowel Disease
- (2013) Neena S. Abraham et al. Clinical Gastroenterology and Hepatology
- Liver Injury From Tumor Necrosis Factor-α Antagonists: Analysis of Thirty-four Cases
- (2013) Marwan Ghabril et al. Clinical Gastroenterology and Hepatology
- Comparative Effectiveness of Infliximab and Adalimumab for Crohn's Disease
- (2013) Mark T. Osterman et al. Clinical Gastroenterology and Hepatology
- Association Between Pharmacokinetics of Adalimumab and Mucosal Healing in Patients With Inflammatory Bowel Diseases
- (2013) Xavier Roblin et al. Clinical Gastroenterology and Hepatology
- Vedolizumab for the Treatment of IBD: A Selective Therapeutic Approach Targeting Pathogenic a4b7 Cells
- (2013) Manol Jovani et al. CURRENT DRUG TARGETS
- Progressive multifocal leukoencephalopathy in patients with multiple sclerosis
- (2013) Kelly J. Baldwin et al. CURRENT OPINION IN NEUROLOGY
- Still in Pursuit
- (2013) Stephen B. Hanauer GASTROENTEROLOGY
- Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis
- (2013) William J. Sandborn et al. GASTROENTEROLOGY
- Combination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative Colitis
- (2013) Remo Panaccione et al. GASTROENTEROLOGY
- Individualised therapy is more cost-effective than dose intensification in patients with Crohn’s disease who lose response to anti-TNF treatment: a randomised, controlled trial
- (2013) Casper Steenholdt et al. GUT
- The Incidence and Predictors of Lupus-like Reaction in Patients with IBD Treated with Anti-TNF Therapies
- (2013) Henit Yanai et al. INFLAMMATORY BOWEL DISEASES
- Serum Adalimumab Concentration and Clinical Remission in Patients with Crohnʼs Disease
- (2013) Yi-Lin Chiu et al. INFLAMMATORY BOWEL DISEASES
- Ten Years of Infliximab for Crohn’s Disease
- (2013) Emma J. Eshuis et al. INFLAMMATORY BOWEL DISEASES
- Feasibility of Endoscopic Assessment and Treating to Target to Achieve Mucosal Healing in Ulcerative Colitis
- (2013) Guillaume Bouguen et al. INFLAMMATORY BOWEL DISEASES
- Infliximab induces a dysregulated tissue-homing profile on human T-lymphocytes in-vitro: A novel mechanism for paradoxical inflammation?
- (2013) Simon T. Peake et al. Journal of Crohns & Colitis
- Tumour necrosis factor and cancer
- (2013) John P Waters et al. JOURNAL OF PATHOLOGY
- Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
- (2013) Brian G. Feagan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
- (2013) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Review article: non-malignant haematological complications of anti-tumour necrosis factor alpha therapy
- (2012) T. Bessissow et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- A Pooled Analysis of Infections, Malignancy and Mortality in Infliximab- and Immunomodulator-Treated Adult Patients With Inflammatory Bowel Disease
- (2012) Gary R Lichtenstein et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Impact of Antibodies to Infliximab on Clinical Outcomes and Serum Infliximab Levels in Patients With Inflammatory Bowel Disease (IBD): A Meta-Analysis
- (2012) Kavinderjit S Nanda et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Serious Infection and Mortality in Patients With Crohn's Disease: More Than 5 Years of Follow-Up in the TREAT™ Registry
- (2012) Gary R Lichtenstein et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Anti-TNF Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacokinetics-Based Dosing Paradigms
- (2012) I Ordás et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study
- (2012) Mirthe Emilie van der Valk et al. GUT
- A histopathologic scoring system as a tool for standardized reporting of chronic (ileo)colitis and independent risk assessment for inflammatory bowel disease
- (2012) Bita V. Naini et al. HUMAN PATHOLOGY
- Update on PML and PML-IRIS Occurring in Multiple Sclerosis Patients Treated With Natalizumab
- (2012) B.K. Kleinschmidt-DeMasters et al. JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY
- Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial
- (2012) David Laharie et al. LANCET
- Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab
- (2012) Per Soelberg Sørensen et al. Multiple Sclerosis Journal
- Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
- (2012) Gary Bloomgren et al. NEW ENGLAND JOURNAL OF MEDICINE
- Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease
- (2011) C. Steenholdt et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Efficacy of Biological Therapies in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis
- (2011) Alexander C Ford et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- The clinical features of PML
- (2011) J. R. BERGER CLEVELAND CLINIC JOURNAL OF MEDICINE
- Certolizumab Pegol for Active Crohn's Disease: A Placebo-Controlled, Randomized Trial
- (2011) William J. Sandborn et al. Clinical Gastroenterology and Hepatology
- Mucosal Healing Predicts Late Outcomes After the First Course of Corticosteroids for Newly Diagnosed Ulcerative Colitis
- (2011) Sandro Ardizzone et al. Clinical Gastroenterology and Hepatology
- Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis
- (2011) William J. Sandborn et al. GASTROENTEROLOGY
- Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases With Time, Based on Systematic Review
- (2011) Natalie A. Molodecky et al. GASTROENTEROLOGY
- Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial
- (2011) W. Reinisch et al. GUT
- Vedolizumab for the Treatment of Active Ulcerative Colitis: A Randomized Controlled Phase 2 Dose-ranging Study
- (2011) Asit Parikh et al. INFLAMMATORY BOWEL DISEASES
- Development of inflammatory bowel disease during anti-TNF-α therapy for inflammatory rheumatic disease. A nationwide series
- (2011) Éric Toussirot et al. JOINT BONE SPINE
- Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease
- (2011) Mamoru Watanabe et al. Journal of Crohns & Colitis
- Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy
- (2011) P. Vermersch et al. NEUROLOGY
- Costs of care for Crohn’s disease following the introduction of infliximab: a single-centre UK experience
- (2010) M. B. Sprakes et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee
- (2010) Asher Kornbluth et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Severe Skin Lesions Cause Patients With Inflammatory Bowel Disease to Discontinue Anti–Tumor Necrosis Factor Therapy
- (2010) Jean–François Rahier et al. Clinical Gastroenterology and Hepatology
- A Systematic Review of Factors That Contribute to Hepatosplenic T-Cell Lymphoma in Patients With Inflammatory Bowel Disease
- (2010) David S. Kotlyar et al. Clinical Gastroenterology and Hepatology
- Monitoring functional serum antitumor necrosis factor antibody level in Crohnʼs disease patients who maintained and those who lost response to anti-TNF
- (2010) Akihiro Yamada et al. INFLAMMATORY BOWEL DISEASES
- Characterization of patients with infliximab-induced lupus erythematosus and outcomes after retreatment with a second anti-TNF agent
- (2010) Sreedhar Subramanian et al. INFLAMMATORY BOWEL DISEASES
- Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease
- (2010) Jean Frédéric Colombel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Meta-analysis: pre-operative infliximab treatment and short-term post-operative complications in patients with ulcerative colitis
- (2009) Z. YANG et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Management of Crohn's Disease in Adults
- (2009) Gary R Lichtenstein et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Progressive Multifocal Leukoencephalopathy in Patients on Immunomodulatory Therapies
- (2009) Eugene O. Major Annual Review of Medicine
- Integrins
- (2009) Malgorzata Barczyk et al. CELL AND TISSUE RESEARCH
- Risk of Lymphoma Associated With Combination Anti–Tumor Necrosis Factor and Immunomodulator Therapy for the Treatment of Crohn's Disease: A Meta-Analysis
- (2009) Corey A. Siegel et al. Clinical Gastroenterology and Hepatology
- Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease
- (2009) Konstantinos Karmiris et al. GASTROENTEROLOGY
- Colectomy Rate Comparison After Treatment of Ulcerative Colitis With Placebo or Infliximab
- (2009) William J. Sandborn et al. GASTROENTEROLOGY
- Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis
- (2009) C H Seow et al. GUT
- Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohnʼs disease
- (2009) Fabian Schnitzler et al. INFLAMMATORY BOWEL DISEASES
- Adalimumab-induced Autoimmune Hepatitis
- (2009) Tomer Adar et al. JOURNAL OF CLINICAL GASTROENTEROLOGY
- Rising Incidence of Inflammatory Bowel Disease Among Children: A 12-year Study
- (2009) Hoda M Malaty et al. JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION
- Cutaneous side effects of anti–tumor necrosis factor biologic therapy: A clinical review
- (2009) Aikaterini-Evaggelia Moustou et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Clinical implications of mucosal healing for the management of IBD
- (2009) Guillaume Pineton de Chambrun et al. Nature Reviews Gastroenterology & Hepatology
- Anti-TNF-induced lupus
- (2009) E. L. Williams et al. RHEUMATOLOGY
- ANCA-Associated Renal Vasculitis Following Anti–Tumor Necrosis Factor α Therapy
- (2008) Roslyn Simms et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Direct Health Care Costs of Crohn's Disease and Ulcerative Colitis in US Children and Adults
- (2008) Michael D. Kappelman et al. GASTROENTEROLOGY
- Infliximab Prevents Crohn's Disease Recurrence After Ileal Resection
- (2008) Miguel Regueiro et al. GASTROENTEROLOGY
- Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study
- (2008) H Fidder et al. GUT
- Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial
- (2008) Geert D'Haens et al. LANCET
- Tumor necrosis factor antagonist mechanisms of action: A comprehensive review
- (2007) Daniel Tracey et al. PHARMACOLOGY & THERAPEUTICS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now